A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers

Neurogastroenterology and Motility

Volumn 19, Issue 3, 2007, Pages 180-187

  Choung, R S ^a   Talley, N J ^a   Peterson, J ^a   Camilleri, M ^a   Burton, D ^a   Harmsen, W S ^a   Zinsmeister, A R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Accommodation; Itopride; Motility; Stomach

Indexed keywords

ENSURE; ITOPRIDE; PERTECHNETIC ACID TC 99M; PLACEBO; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; INTESTINE TRANSIT TIME; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SENSORIMOTOR FUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH EMPTYING; STOMACH FUNCTION; STOMACH MOTILITY; STOMACH VOLUME;

BENZAMIDES; BENZYL COMPOUNDS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; HUMANS; MALE; SATIATION; STOMACH; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33846916642     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2006.00869.x     Document Type: Article

References (34)

1. Talley NJ, Zinsmeister AR, Schleck CD, Melton L Jr. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
2. Talley NJ, Stanghellini V, Heading R, Koch KL, Malagelada JR, Tytgat GNJ. Functional gastroduodenal disorders: a working team report for the Rome II consensus on functional gastrointestinal disorders. Gut 1999; 45 (Suppl. 2): II37-42.
3. Drossman D, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
4. Camilleri M, Dubois D, Coulie B et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3: 543-52.
5. Iwanaga Y, Miyashita N, Morikawa K, Mizumoto A, Kondo Y, Itoh Z. A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine. Gastroenterology 1990; 99: 401-8.
6. Iwanaga Y, Kimura T, Miyashita N et al. Characterization of acetylcholinesterase-inhibition by itopride. Jpn J Pharmacol 1994; 66: 317-22.
7. Tsubouchi T, Saito T, Mizutani F, Yamauchi T, Iwanaga Y. Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003; 306: 787-93.
8. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832-40.
9. Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998; 12: 761-6.
10. Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J. Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 2003; 52: 1271-7.
11. Liau SS, Camilleri M, Kim DY, Stephens D, Burton DD, O'Connor MK. Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging. Neurogastroenterol Motil 2001; 13: 533-42.
12. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-52.
13. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006; in press.
14. Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med 1989; 111: 671-4.
15. Mushiroda T, Douya R, Takahara E, Nagata O. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 2000; 28: 1231-7.
16. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
17. Chial HJ, Camilleri C, Delgado-Aros S et al. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil 2002; 14: 249-53.
18. Kuiken SD, Samsom M, Camilleri M et al. Development of a test to measure gastric accommodation in humans. Am J Physiol 1999; 277 (6 Pt 1): G1217-21.
19. Thumshirn M, Camilleri M, Saslow SB, Williams DE, Burton DD, Hanson RB. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut 1999; 44: 55-64.
20. van den Elzen BD, Boeckxstaens GE. Review article: a critical view on impaired accommodation as therapeutic target for functional dyspepsia. Aliment Pharmacol Ther 2006; 23: 1499-10.
21. Bouras EP, Delgado-Aros S, Camilleri M et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 2002; 51: 781-6.
22. Thumshirn M, Camilleri M, Choi MG, Zinsmeister AR. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology 1999; 116: 573-85.
23. Cuomo R, Vandaele P, Coulie B et al. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am J Gastroenterol 2006; 101: 804-11.
24. Tack J, Demedts I, Meulemans A, Schuurkes J, Janssens J. Role of nitric oxide in the gastric accommodation reflex and in meal induced satiety in humans. Gut 2002; 51: 219-24.
25. Tack J. Functional dyspepsia: impaired fundic accommodation. Curr Treat Options Gastroenterol 2000; 3: 287-94.
26. Delgado-Aros S, Camilleri M, Cremonini F, Ferber I, Stephens D, Burton DD. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004; 127: 1685-94.
27. Harasawa S, Miwa T. Effect of itopride hydrochloride on gastric emptying in chronic gastritis patients (in Japanese). Jpn Pharmacol Ther 1993; 21: 303-9.
28. Siegel JA, Urbain JL, Adler LP et al. Biphasic nature of gastric emptying. Gut 1988; 29: 85-9.
29. Johnson AG. The effects of cisapride on antroduodenal co-ordination and gastric emptying. Scand J Gastroenterol Suppl 1989; 165: 36-43.
30. Wishart JM, Horowitz M, Campbell J, Jones KL. The effect of cisapride on oral and intravenous glucose tolerance in normal subjects. J Gastroenterol Hepatol 1997; 12: 795-800.
31. Jones KL, Horowitz M, Carney BI, Sun WM, Chatterton BE. Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness. Gut 1996; 38: 310-5.
32. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-35.
33. Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998; 42: 814-22.
34. Katagiri F, Shiga T, Inoue S, Sato Y, Itoh H, Takeyama M. Effects of itopride hydrochloride on plasma gut-regulatory peptide and stress-related hormone levels in healthy human subjects. Pharmacology 2006; 77: 115-21.